<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.05.08.21256866</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Infectious Diseases (except HIV/AIDS)</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Antibody Responses After a Single Dose of ChAdOx1 nCoV-19 Vaccine in Healthcare Workers Previously Infected with SARS-CoV-2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Havervall</surname><given-names>Sebastian</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">&#x0023;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Marking</surname><given-names>Ulrika</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">&#x0023;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Greilert-Norin</surname><given-names>Nina</given-names></name>
<degrees>RN</degrees>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ng</surname><given-names>Henry</given-names></name>
<degrees>MMSc</degrees>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Salomonsson</surname><given-names>Ann-Christin</given-names></name>
<degrees>BSc</degrees>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hellstr&#x00F6;m</surname><given-names>Cecilia</given-names></name>
<xref ref-type="aff" rid="a3">3</xref>
<degrees>MSc</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Pin</surname><given-names>Elisa</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Blom</surname><given-names>Kim</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mangsbo</surname><given-names>Sara</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Phillipson</surname><given-names>Mia</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Klingstr&#x00F6;m</surname><given-names>Jonas</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>&#x00C5;berg</surname><given-names>Mikael</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hober</surname><given-names>Sophia</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nilsson</surname><given-names>Peter</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Th&#x00E5;lin</surname><given-names>Charlotte</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital</institution>, Stockholm, <country>Sweden</country></aff>
<aff id="a2"><label>2</label><institution>Department of Medical Cell Biology and Science for Life Laboratory Uppsala University</institution>, Uppsala, <country>Sweden</country></aff>
<aff id="a3"><label>3</label><institution>Department of Protein Science, KTH Royal Institute of Technology</institution>, Stockholm, <country>Sweden</country></aff>
<aff id="a4"><label>4</label><institution>Public Health Agency of Sweden</institution>, Solna, <country>Sweden</country></aff>
<aff id="a5"><label>5</label><institution>Department of Pharmaceutical Biosciences, Uppsala University</institution>, Uppsala, <country>Sweden</country></aff>
<aff id="a6"><label>6</label><institution>Centre for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet</institution>, Stockholm, <country>Sweden</country></aff>
<aff id="a7"><label>7</label><institution>Department of Medical Sciences, Clinical Chemistry and Science for Life Laboratory, Uppsala University</institution>, Uppsala, <country>Sweden</country></aff>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="equal"><label>&#x0023;</label><p>these authors contributed equally</p></fn>
<corresp id="cor1"><label>&#x002A;</label>Corresponding author: Charlotte Th&#x00E5;lin, M.D., Ph.D., Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 18288 Stockholm, Sweden, Phone: 08-12355000, E-mail: <email>charlotte.thalin@sll.se</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<year>2021</year>
</pub-date>
<elocation-id>2021.05.08.21256866</elocation-id>
<history>
<date date-type="received">
<day>08</day>
<month>5</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>08</day>
<month>5</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>5</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license><license-p>The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.</license-p></license>
</permissions>
<self-uri xlink:href="21256866.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<sec>
<title>Background</title>
<p>Recent reports demonstrate robust serological responses to a single dose of messenger RNA (mRNA) vaccines in individuals previously infected with SARS-CoV-2. Data on immune responses following a single-dose adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein (ChAdOx1 nCoV-19) in individuals with previous SARS-CoV-2 infection are however limited, and current guidelines recommend a two-dose regime regardless of preexisting immunity.</p></sec>
<sec>
<title>Methods</title>
<p>We compared spike-specific IgG and pseudo-neutralizing spike-ACE2 blocking antibodies against SARS-CoV-2 wild type and variants B.1.1.7, B.1.351, and P1 following two doses of the mRNA vaccine BNT162b2 and a single dose of the adenovector vaccine ChAdOx1 nCoV-19 in 232 healthcare workers with and without previous COVID-19.</p></sec>
<sec>
<title>Findings</title>
<p>The post-vaccine levels of spike-specific IgG and neutralizing antibodies against the SARS-CoV-2 wild type and all three variants of concern were similar or higher in participants receiving a single dose of ChAdOx1 nCoV-19 vaccine post SARS-CoV-2 infection (both &#x003C; 11 months post infection (n=37) and &#x2265; 11 months infection (n=46)) compared to participants who received two doses of BNT162b2 vaccine (n=149).</p></sec>
<sec>
<title>Interpretation</title>
<p>Our data support that a single dose ChAdOx1 nCoV-19 vaccine serves as an effective immune booster after priming with natural SARS-CoV-2 infection up to at least 11 months post infection.</p></sec>
</abstract>
<counts>
<page-count count="9"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>This work was funded by Jonas &amp; Christina af Jochnick foundation; Lundblad family foundation; Region Stockholm; Knut and Alice Wallenberg foundation; Science for Life Laboratory (SciLifeLab); Erling-Persson family foundation. The funders of the study had no role in study design, data analysis, data collection, data interpretation, or writing of the manuscript.</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>The study was approved by the Swedish Ethical Review Authority, and informed written consent was obtained from all participants.</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Recent reports demonstrate robust serological responses to a single dose of messenger RNA (mRNA) vaccines in individuals previously infected with SARS-CoV-2. These individuals develop spike-specific IgG and neutralizing antibody titers after one dose that are equivalent to or exceeding those observed after the second dose in vaccinees without preexisting immunity (<xref ref-type="bibr" rid="c1">1</xref>-<xref ref-type="bibr" rid="c7">7</xref>). In a study of 23 SARS-CoV-2 experienced individuals, a substantial enhancement of neutralizing antibody response against SARS-CoV-2 variants B.1.1.7 and B.1.351 by a single dose mRNA vaccine was noted (<xref ref-type="bibr" rid="c6">6</xref>). A second dose mRNA vaccine to individuals with prior SARS-CoV-2 infection add little value in terms of serological titers (<xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c7">7</xref>), and may be associated with increased risk of non-severe adverse events (<xref ref-type="bibr" rid="c8">8</xref>). Data on immune responses following a single-dose adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein such as ChAdOx1 nCoV-19 in individuals with previous SARS-CoV-2 infection are however limited. Current guidelines recommend a two-dose regime regardless of preexisting immunity (<xref ref-type="bibr" rid="c9">9</xref>).</p>
<p>We compared spike-specific IgG and their neutralizing capacity towards SARS-CoV-2 wild type and three variants of concern following two doses of the mRNA vaccine BNT162b2 and a single dose of the adenovector vaccine ChAdOx1 nCoV-19 in healthcare workers with and without previous COVID-19.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<p>The COMMUNITY (COVID-19 Biomarker and Immunity) study (<xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c11">11</xref>) investigates long-term immunity after COVID-19 in 2149 healthcare workers at Danderyd Hospital, Stockholm, Sweden, included between April 15th and May 8th 2020. Blood samples are obtained every four months and SARS-CoV-2 spike-specific IgG are analyzed by multiplex antigen bead array (FlexMap3D, Luminex Corp) as previously described (<xref ref-type="bibr" rid="c10">10</xref>).</p>
<p>Between March 23rd and 31st, 2021, this sub study investigated serological responses following either two doses of BNT162b2 or one dose of ChAdOx1 nCoV-19 vaccination in 232 study participants with or without previous SARS-CoV-2 infection confirmed by seroconversion. Of these, 149 participants received two doses of BNT162b2 vaccine (36 previously infected participants with median age 52 (IQR 41-62), 86&#x0025; female, and 113 SARS-CoV-2-na&#x00EF;ve participants with median age 53 (IQR 42-58), 86 &#x0025; women), and 83 participants received a single-dose ChAdOx1 nCoV-19 vaccine (46 participants &#x2265; 11 months post SARS-CoV-2 infection with median age 49 (IQR 41-60), 83&#x0025; female, and 37 participants &#x003C; 11 months post SARS-CoV-2 infection with median age 48 (IQR 40-54), 95 &#x0025; women). 162 unvaccinated previously SARS-CoV-2 infected study participants with median age 49 (IQR 40-76), 93&#x0025; female, and 80 unvaccinated seronegative study participants with median age 51 (IQR 41-58), 91&#x0025; female, were enrolled as control groups.</p>
<p>Blood samples were collected at least two weeks post second dose BNT162b2 or at least one week post single dose ChAdOx1 nCoV-19 vaccination. Spike-specific IgG and their neutralizing capacity (analyzed by a pseudo-neutralizing spike-ACE2 assay) against SARS-CoV-2 wild type and variants B.1.1.7, B.1.351, and P1 were measured using the V-PLEX SARS-CoV-2 Panel 7 (IgG and ACE2, Meso Scale Diagnostics, USA) and expressed as arbitrary units (AU)/ml. For validation, spike-specific IgG antibodies against SARS-CoV-2 wild type were measured in the same samples using the multiplex antigen bead array (FlexMap3D, Luminex Corp) (<xref ref-type="bibr" rid="c10">10</xref>). Group comparisons were performed using Dunn&#x2019;s Kruskal-Wallis multiple comparison test. The statistical significance threshold was set at 5&#x0025;. Analyses were performed using GraphPad Prism 9.1.0 (GraphPad Software, Inc, USA). The study was approved by the Swedish Ethical Review Authority, and informed written consent was obtained from all participants.</p>
<sec id="s2a">
<title>Role of the funding source</title>
<p>The funders of the study had no role in study design, data analysis, data collection, data interpretation, or writing of the manuscript.</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<p>The median levels of spike-specific IgG antibodies against the SARS-CoV-2 wild type and variants of concern B.1.1.7, B.1.351 and P1 were similar or higher in participants post SARS-CoV-2 infection (both &#x003C; 11 months post infection and &#x2265; 11 months post infection) receiving a single dose ChAdOx1 nCoV-19 vaccine compared to participants who received two doses BNT162b2 vaccine (<xref rid="fig1" ref-type="fig">Figure 1 A-D</xref>, Figure S1). Neutralizing antibodies towards the SARS-CoV-2 wild type and all three variants reached higher levels in previously infected vaccinees receiving a single dose ChAdOx1 nCoV-19 vaccine than in participants fully vaccinated with BNT162b2 (<xref rid="fig2" ref-type="fig">Figure 2B-D</xref>).</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Spike-specific IgG responses against SARS-CoV-2 wild type and variants following two doses BNT162b2 in individuals with or without previous SARS-CoV-2 infection or one dose ChAdOx1 nCoV-19 vaccine in individuals with previous SARS-CoV-2 infection.</title>
<p>A) Spike-specific IgG responses against wild type (A), B.1.1.7 (B), B.1.351 (C) and P1 (D). Numbers above each cluster indicate median AU/ml. Lines indicate medians with interquartile ranges. AU; arbitrary units, mpi; months post infection, ns; non-significant, &#x002A;; p&#x003C;0.05, &#x002A;&#x002A;; p&#x003C;0,01 &#x002A;&#x002A;&#x002A;; p&#x003C;0.001, &#x002A;&#x002A;&#x002A;&#x002A;; p&#x003C;0.0001.</p></caption>
<graphic xlink:href="21256866v1_fig1.tif"/>
</fig>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Neutralizing antibody responses against SARS-CoV-2 wild type and variants following two doses BNT162b2 in individuals with or without previous SARS-CoV-2 infection or one dose ChAdOx1 nCoV-19 vaccine in individuals with previous SARS-CoV-2 infection.</title>
<p>Neutralizing antibody responses against wild type (A), B.1.1.7 (B), B.1.351 (C) and P1 (D). Numbers above each cluster indicate median AU/ml. Lines indicate medians with interquartile ranges. AU; arbitrary units, mpi; months post infection, ns; non-significant, &#x002A;; p&#x003C;0.05, &#x002A;&#x002A;; p&#x003C;0,01 &#x002A;&#x002A;&#x002A;; p&#x003C;0.001, &#x002A;&#x002A;&#x002A;&#x002A;; p&#x003C;0.0001.</p></caption>
<graphic xlink:href="21256866v1_fig2.tif"/>
</fig>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>A single dose of the adenovector vaccine ChAdOx1 nCoV-19 following natural infection elicited a robust serological response with broad neutralizing capacity against SARS-CoV-2 wild type and variants of concern. Neutralizing antibody levels exceeded those after two doses of the mRNA vaccine BNT162b2. Our data support that a single dose of adenovector vaccine serves as an efficacious immune booster after priming with natural SARS-CoV-2 infection up to at least 11 months post infection.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material>
<label>Supplemental Figure 1</label>
<media xlink:href="supplements/256866_file02.docx" />
</supplementary-material>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>Data is available upon reasonable request</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>This work was funded by Jonas &#x0026; Christina af Jochnick foundation; Lundblad family foundation; Region Stockholm; Knut and Alice Wallenberg foundation; Science for Life Laboratory (SciLifeLab); Erling-Persson family foundation.</p>
</ack>
<sec id="s5">
<title>Conflict of interest</title>
<p>The authors declare no competing interests.</p>
</sec>
<sec id="s6">
<title>Author contribution</title>
<p>SeH, UM, PN and CT had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. SeH, UM, and CT designed the study, made statistical analysis, and drafted the manuscript. NG, HN, ACS, CH, EP, M&#x00C5; conducted the analysis and the administrative and material support. SeH, UM, KB, SM, JK, MP, M&#x00C5;, SoH, PN, CT interpreted the data, and all authors critically revised the manuscript. SoH, PN, CT obtained funding. MP, SoH, PN, CT supervised. All authors had final responsibility for the decision to submit for publication.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Krammer</surname> <given-names>F</given-names></string-name>, <string-name><surname>Srivastava</surname> <given-names>K</given-names></string-name>, <string-name><surname>Alshammary</surname> <given-names>H</given-names></string-name>, <string-name><surname>Amoako</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Awawda</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Beach</surname> <given-names>KF</given-names></string-name>, <string-name><surname>Berm&#x00FA;dez-Gonz&#x00E1;lez</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Bielak</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Carre&#x00F1;o</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Chernet</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Eaker</surname> <given-names>LQ</given-names></string-name>, <string-name><surname>Ferreri</surname> <given-names>ED</given-names></string-name>, <string-name><surname>Floda</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Gleason</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Hamburger</surname> <given-names>JZ</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kleiner</surname> <given-names>G</given-names></string-name>, <string-name><surname>Jurczyszak</surname> <given-names>D</given-names></string-name>, <string-name><surname>Matthews</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Mendez</surname> <given-names>WA</given-names></string-name>, <string-name><surname>Nabeel</surname> <given-names>I</given-names></string-name>, <string-name><surname>Mulder</surname> <given-names>LCF</given-names></string-name>, <string-name><surname>Raskin</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Russo</surname> <given-names>KT</given-names></string-name>, <string-name><surname>Salimbangon</surname> <given-names>AT</given-names></string-name>, <string-name><surname>Saksena</surname> <given-names>M</given-names></string-name>, <string-name><surname>Shin</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>G</given-names></string-name>, <string-name><surname>Sominsky</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Stadlbauer</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wajnberg</surname> <given-names>A</given-names></string-name>, <string-name><surname>Simon</surname> <given-names>V.</given-names></string-name> <article-title>Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine</article-title>. <source>The New England journal of medicine</source>. <year>2021</year>;<volume>384</volume>:<fpage>1372</fpage>&#x2013;<lpage>1374</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Saadat</surname> <given-names>S</given-names></string-name>, <string-name><surname>Rikhtegaran Tehrani</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Logue</surname> <given-names>J</given-names></string-name>, <string-name><surname>Newman</surname> <given-names>M</given-names></string-name>, <string-name><surname>Frieman</surname> <given-names>MB</given-names></string-name>, <string-name><surname>Harris</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Sajadi</surname> <given-names>MM</given-names></string-name>. <article-title>Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2</article-title>. <source>Jama</source>. <year>2021</year>;<volume>325</volume>:<fpage>1467</fpage>&#x2013;<lpage>1469</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Manisty</surname> <given-names>C</given-names></string-name>, <string-name><surname>Otter</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Treibel</surname> <given-names>TA</given-names></string-name>, <string-name><surname>McKnight</surname> <given-names>&#x00C1;</given-names></string-name>, <string-name><surname>Altmann</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Brooks</surname> <given-names>T</given-names></string-name>, <string-name><surname>Noursadeghi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Boyton</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Semper</surname> <given-names>A</given-names></string-name>, <string-name><surname>Moon</surname> <given-names>JC</given-names></string-name>. <article-title>Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals</article-title>. <source>Lancet (London, England)</source>. <year>2021</year>;<volume>397</volume>:<fpage>1057</fpage>&#x2013;<lpage>1058</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Subbarao</surname> <given-names>S</given-names></string-name>, <string-name><surname>Warrener</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Hoschler</surname> <given-names>K</given-names></string-name>, <string-name><surname>Perry</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Shute</surname> <given-names>J</given-names></string-name>, <string-name><surname>Whitaker</surname> <given-names>H</given-names></string-name>, <string-name><surname>O&#x2019;Brien</surname> <given-names>M</given-names></string-name>, <string-name><surname>Baawuah</surname> <given-names>F</given-names></string-name>, <string-name><surname>Moss</surname> <given-names>P</given-names></string-name>, <string-name><surname>Parry</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ladhani</surname> <given-names>SN</given-names></string-name>, <string-name><surname>Ramsay</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Brown</surname> <given-names>KE</given-names></string-name>, <string-name><surname>Amirthalingam</surname> <given-names>G.</given-names></string-name> <article-title>Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021</article-title>. <source>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</source>. <year>2021</year>;<volume>26</volume>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="other"><string-name><surname>Blain</surname> <given-names>H</given-names></string-name>, <string-name><surname>Tuaillon</surname> <given-names>E</given-names></string-name>, <string-name><surname>Gamon</surname> <given-names>L</given-names></string-name>, <string-name><surname>Pisoni</surname> <given-names>A</given-names></string-name>, <string-name><surname>Miot</surname> <given-names>S</given-names></string-name>, <string-name><surname>Picot</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Bousquet</surname> <given-names>J.</given-names></string-name> <article-title>Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose</article-title>. <source>Jama</source>. <year>2021</year>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="book"><string-name><surname>Reynolds</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Pade</surname> <given-names>C</given-names></string-name>, <string-name><surname>Gibbons</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Butler</surname> <given-names>DK</given-names></string-name>, <string-name><surname>Otter</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Menacho</surname> <given-names>K</given-names></string-name>, <string-name><surname>Fontana</surname> <given-names>M</given-names></string-name>, <string-name><surname>Smit</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sackville-West</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Cutino-Moguel</surname> <given-names>T</given-names></string-name>, <string-name><surname>Maini</surname> <given-names>MK</given-names></string-name>, <string-name><surname>Chain</surname> <given-names>B</given-names></string-name>, <string-name><surname>Noursadeghi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Brooks</surname> <given-names>T</given-names></string-name>, <string-name><surname>Semper</surname> <given-names>A</given-names></string-name>, <string-name><surname>Manisty</surname> <given-names>C</given-names></string-name>, <string-name><surname>Treibel</surname> <given-names>TA</given-names></string-name>, <string-name><surname>Moon</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Valdes</surname> <given-names>AM</given-names></string-name>, <string-name><surname>McKnight</surname> <given-names>&#x00C1;</given-names></string-name>, <string-name><surname>Altmann</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Boyton</surname> <given-names>R.</given-names></string-name> <chapter-title>Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose</chapter-title>. <source>Science</source> (<publisher-loc>New York, NY</publisher-loc>). <year>2021</year>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="other"><string-name><surname>Goel</surname> <given-names>RR</given-names></string-name>, <string-name><surname>Apostolidis</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Painter</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Mathew</surname> <given-names>D</given-names></string-name>, <string-name><surname>Pattekar</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kuthuru</surname> <given-names>O</given-names></string-name>, <string-name><surname>Gouma</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hicks</surname> <given-names>P</given-names></string-name>, <string-name><surname>Meng</surname> <given-names>W</given-names></string-name>, <string-name><surname>Rosenfeld</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Dysinger</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lundgreen</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Kuri-Cervantes</surname> <given-names>L</given-names></string-name>, <string-name><surname>Adamski</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hicks</surname> <given-names>A</given-names></string-name>, <string-name><surname>Korte</surname> <given-names>S</given-names></string-name>, <string-name><surname>Oldridge</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Baxter</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Giles</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Weirick</surname> <given-names>ME</given-names></string-name>, <string-name><surname>McAllister</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Dougherty</surname> <given-names>J</given-names></string-name>, <string-name><surname>Long</surname> <given-names>S</given-names></string-name>, <string-name><surname>D&#x2019;Andrea</surname> <given-names>K</given-names></string-name>, <string-name><surname>Hamilton</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Betts</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Luning Prak</surname> <given-names>ET</given-names></string-name>, <string-name><surname>Bates</surname> <given-names>P</given-names></string-name>, <string-name><surname>Hensley</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Greenplate</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Wherry</surname> <given-names>EJ</given-names></string-name>. <article-title>Distinct antibody and memory B cell responses in SARS-CoV-2 na&#x00EF;ve and recovered individuals following mRNA vaccination</article-title>. <source>Science immunology</source>. <year>2021;6</year>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Mathioudakis</surname> <given-names>AG</given-names></string-name>, <string-name><surname>Ghrew</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ustianowski</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ahmad</surname> <given-names>S</given-names></string-name>, <string-name><surname>Borrow</surname> <given-names>R</given-names></string-name>, <string-name><surname>Papavasileiou</surname> <given-names>LP</given-names></string-name>, <string-name><surname>Petrakis</surname> <given-names>D</given-names></string-name>, <string-name><surname>Bakerly</surname> <given-names>ND</given-names></string-name>. <source>Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. Life (Basel, Switzerland)</source>. <year>2021</year>;<volume>11</volume>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="website"><string-name><surname>Sage</surname> <given-names>W.</given-names></string-name> <source>Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience)</source>. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1">https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1</ext-link>: <year>2021</year> First issued 10 February, updated 21 April. Report No.: WHO/2019-nCoV/vaccines/SAGE_recommendation/AZD1222/2021.2.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Rudberg</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Havervall</surname> <given-names>S</given-names></string-name>, <string-name><surname>Manberg</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jernbom Falk</surname> <given-names>A</given-names></string-name>, <string-name><surname>Aguilera</surname> <given-names>K</given-names></string-name>, <string-name><surname>Ng</surname> <given-names>H</given-names></string-name>, <string-name><surname>Gabrielsson</surname> <given-names>L</given-names></string-name>, <string-name><surname>Salomonsson</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Hanke</surname> <given-names>L</given-names></string-name>, <string-name><surname>Murrell</surname> <given-names>B</given-names></string-name>, <string-name><surname>McInerney</surname> <given-names>G</given-names></string-name>, <string-name><surname>Olofsson</surname> <given-names>J</given-names></string-name>, <string-name><surname>Andersson</surname> <given-names>E</given-names></string-name>, <string-name><surname>Hellstrom</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bayati</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bergstrom</surname> <given-names>S</given-names></string-name>, <string-name><surname>Pin</surname> <given-names>E</given-names></string-name>, <string-name><surname>Sjoberg</surname> <given-names>R</given-names></string-name>, <string-name><surname>Tegel</surname> <given-names>H</given-names></string-name>, <string-name><surname>Hedhammar</surname> <given-names>M</given-names></string-name>, <string-name><surname>Phillipson</surname> <given-names>M</given-names></string-name>, <string-name><surname>Nilsson</surname> <given-names>P</given-names></string-name>, <string-name><surname>Hober</surname> <given-names>S</given-names></string-name>, <string-name><surname>Thalin</surname> <given-names>C.</given-names></string-name> <article-title>SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden</article-title>. <source>Nature communications</source>. <year>2020</year>;<volume>11</volume>:<fpage>5064</fpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="other"><string-name><surname>Havervall</surname> <given-names>S</given-names></string-name>, <string-name><surname>Rosell</surname> <given-names>A</given-names></string-name>, <string-name><surname>Phillipson</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mangsbo</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Nilsson</surname> <given-names>P</given-names></string-name>, <string-name><surname>Hober</surname> <given-names>S</given-names></string-name>, <string-name><surname>Thalin</surname> <given-names>C.</given-names></string-name> <article-title>Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers</article-title>. <source>Jama</source>. <year>2021</year>.</mixed-citation></ref>
</ref-list>
</back>
</article>